Mixed Bag For Biopharma Funding In 2025: Dispatches From J.P. Morgan, Biotech Showcase

Macro Issues A Challenge, Biotech Fundamentals Positive

 
• By Mandy Jackson
Biopharma valuations have leveled off from past declines, but struggle to stay positive (Shutterstock)

More from In Vivo

More from Market Intelligence